Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

Biotechnology

Healthcare
$95.05 +0.77%

+$0.42 today

Market cap
$7.47B
Beta
0.12
P/E (TTM)
57.2
EPS (TTM)
$0.95
52W Low $26.27High $59.87

Volume 0.33M

Average 0.66M

KNSA Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Kiniksa Pharmaceuticals, Ltd.NASDAQ: KNSA

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin narrows to 10.4%

Net margin was 10.4% in Q2 FY2026, down 0.9 pp from a year earlier. On a trailing-twelve-month basis it was 9.6%, up 8.7 pp year over year. Over 3 fiscal years it narrowed by 74.6 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 5 analysts of 11.1% for the fiscal year ending Dec 2026, up from 8.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
10.4%-0.1 pp QoQ
Last fiscal yearDec 2025
8.7%+18.9 pp YoY
LTMJun 2026
9.6%+8.7 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-0.9 pp+1.9 pp+2.8 pp
1 year+18.9 pp+2.4 pp-16.5 pp
3 years-74.6 pp+3.4 pp+78.0 pp
5 years+19.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
8.7%
Year-over-year change
+18.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How KNSA compares with its peers on the latest reported figures

  • KNSA's LTM Jun 2026 net margin of 9.6% is the 2nd highest of the 9 companies compared; the peer median is -562.1%.
  • Its year-over-year change of +8.7 pp is the 4th highest of 7, against a peer median of +61.0 pp.
  • Over three fiscal years its change of -74.6 pp compares with a peer median of -271.7 pp.
KNSA Competitors Peer median
Net Margin for KNSA and competitors
Company Period LTM level YoY 3-year change
NRIXNurix Therapeutics, Inc.LTM Aug 202642.0% +334.5 pp+152.0 pp
KNSAKiniksa Pharmaceuticals, Ltd.LTM Jun 20269.6% +8.7 pp-74.6 pp
PHARPharming Group N.V.LTM Mar 20263.3% +7.7 pp-5.9 pp
ANABAnaptysBio, Inc.LTM Mar 2026-11.5% +114.2 pp+1245.7 pp
SYRESpyre Therapeutics, Inc.LTM Sep 2026-291.6% ——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-832.6% -100.2 pp-537.5 pp
DNTHDianthus Therapeutics, Inc.LTM Jun 2026-1570.9% +793.3 pp-7529.6 pp
IMVTImmunovant, Inc.LTM Sep 2026-7173.5% ——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-143627.1% -160183.1 pp-132411.6 pp
ORKAOruka Therapeutics, Inc.FY2025— ——
Peer median (excluding KNSA) -562.1%+61.0 pp-271.7 pp

Competitors are the stored peer set for KNSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue38.54M220.18M270.26M423.24M677.56M
Cost of Revenue9.1M22.9M56.52M60.91M307.41M
Gross Profit29.44M197.29M213.74M362.33M370.15M
Gross Margin76.4%89.6%79.1%85.6%54.6%
Research & Development99.3M65.49M76.1M111.62M96.85M
Selling, General & Admin85.95M97.95M129.43M168.01M196.27M
Operating Expenses186.08M187.51M238.93M407.95M292.93M
Depreciation & Amortization2.36M2.4M2.34M1.7M1.55M
EBITDA(154.18M)13.43M(14.31M)(34.46M)90.42M
EBITDA Margin-400.0%6.1%-5.3%-8.1%13.3%
Operating Income(156.64M)9.77M(25.2M)(45.62M)77.22M
Operating Margin-406.4%4.4%-9.3%-10.8%11.4%
Interest Income97K1.25M8.54M9.46M11.65M
Interest Expense00000
Other Income / Expenses97K1.25M8.54M9.46M11.65M
Income Before Tax(156.54M)11.03M(16.65M)(36.15M)88.87M
Pre-Tax Margin-406.1%5.0%-6.2%-8.5%13.1%
Income Tax Expense1.39M(172.34M)(30.74M)7.04M29.86M
Net Income(157.92M)183.36M14.08M(43.19M)59.01M
Net Margin-409.7%83.3%5.2%-10.2%8.7%
EPS (Basic)(2.30)2.640.20(0.60)0.80
EPS (Diluted)(2.30)2.600.20(0.60)0.75
Weighted Avg Shares68.58M69.38M70.06M71.42M74.2M
Weighted Avg Shares (Diluted)68.58M70.42M71.92M71.42M78.98M

Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

Intrinsic Alpha fair value

Locked

Current Price

$95.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.